Type II Diabetes Clinical Trial
Official title:
Evaluation of the Fractyl Duodenal Remodeling System for the Treatment of Type 2 Diabetes
NCT number | NCT01927562 |
Other study ID # | C-10000 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | July 13, 2013 |
Est. completion date | March 16, 2018 |
Verified date | February 2024 |
Source | Fractyl Health Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to assess the safety and feasibility of the Fractyl Duodenal Remodeling System for the treatment of patients with poorly controlled Type 2 Diabetes.
Status | Completed |
Enrollment | 57 |
Est. completion date | March 16, 2018 |
Est. primary completion date | April 7, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 28 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Participants Age > 28 years and = 75 years 2. Male or Female 3. Participants with Type 2 Diabetes who are treated for = 10 years and are on stable oral diabetic medications for a minimum of 3 months 4. Participants with an HbA1c > 7.5 and = 10.0% 5. Participants with a BMI > 24 and < 40 6. Participants willing to comply with study requirements and able to understand and comply with informed consent 7. Participants who have signed an informed consent form Exclusion Criteria: 1. Participants diagnosed with Type I Diabetes or with a history of ketoacidosis 2. Participants using insulin for more than 12 months 3. Participants with probable insulin production failure (defined as fasting C Peptide serum <1ng/mL) 4. Participants that have known autoimmune disease as evidenced by a positive anti glutamic acid decarboxylase (GAD) blood test 5. Participants requiring prescription anticoagulation therapy and/or dual anti-platelet therapy including aspirin who cannot discontinue their medication for 14 days before and 14 days after the procedure 6. Participants with iron deficiency anemia - either currently or in their history 7. Participants with current symptomatic hypocalcemia or vitamin D deficiency (routine calcium and/or vitamin D supplementation would not be excluded) 8. Participants with or a history of abnormalities of the GI tract preventing endoscopic access to the duodenum, 9. Participants with symptomatic gallstones or kidney stones at the time of screening 10. Participants with a history of pancreatitis 11. Participants with an active systemic infection 12. Participants with or a history of coagulopathy, upper gastro-intestinal bleeding c conditions such as ulcers, gastric varices, strictures, congenital or acquired intestinal telangiectasia 13. Participants with celiac disease 14. Participants with active malignancy. Those who have had remedial treatment and/or are cancer free for 5 years can be enrolled 15. Participants with known active hepatitis or active liver disease 16. Participants emotionally unstable or who exhibit psychological characteristics which, in the opinion of the Investigator, make the participant a poor candidate for clinical trial participation 17. Participants with previous GI surgery that could affect the ability to treat the duodenum such as participants who have had a Bilroth 2, Roux-en-Y gastric bypass, or other similar procedures or conditions 18. Participants unable to discontinue NSAIDs (non-steroidal anti-inflammatory drugs) during treatment through 2 weeks post procedure phase 19. Participants receiving weight loss medications such as Meridia, Xenical, or over the counter weight loss medications 20. Participant with a known diagnosis or pre-existing symptoms of systemic lupus erythematosus, scleroderma or other autoimmune connective tissue disorder 21. Participants with active and uncontrolled gastroesophageal reflux disease (GERD) defined as grade II esophagitis or greater 22. Participants with active illicit substance abuse or alcoholism 23. Participants participating in another ongoing investigational clinical trial 24. Participants taking corticosteroids or drugs known to affect GI motility (i.e. Reglan) 25. Participants who are not potential candidates for duodenal exclusion surgery or general anesthesia |
Country | Name | City | State |
---|---|---|---|
Chile | INDISA | Santiago |
Lead Sponsor | Collaborator |
---|---|
Fractyl Health Inc. |
Chile,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changed in Mixed Meal Tolerance From Baseline to 3 Months | Improvement in fasting plasma glucose based on Mixed Meal Tolerance Test between baseline and 3 months | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02127762 -
The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy
|
N/A | |
Withdrawn |
NCT04569214 -
The Efficacy and Safety of PAZ320 on PPG and Insulin Blood Levels in Type II Diabetic Patients
|
Phase 2 | |
Completed |
NCT01698528 -
Evaluation of a Prototype Diabetes Management System Applied to Insulin Initiation and Titration
|
N/A | |
Completed |
NCT00985114 -
Safety and Efficacy Study of EndoBarrier in Subjects With Type II Diabetes and Obesity
|
N/A | |
Active, not recruiting |
NCT05120219 -
A Study to Assess the Effect of Food on HR20033 and Pharmacokinetic After Multiple Dose in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04893135 -
Impact of the Rapid Normalization of Chronic Hyperglycemia and the Practice of Moderate Physical Activity on the "Receptor Activator of Nuclear Factor-kappa B Ligand / Osteoprotégérine (RANKL / OPG) System in Patients Living With Type II Diabetes
|
N/A | |
Not yet recruiting |
NCT05108350 -
A Study to Assess the Bioequivalence of Fixed Dose Combination of HR20033 Relative to Co-administration of the Individual Components in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT02586129 -
Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II Diabetes
|
Phase 3 | |
Completed |
NCT02914743 -
Providing Preventive Periodontal Treatment to Hospitalized Patients With Diabetes
|
N/A | |
Completed |
NCT04540016 -
Mass Balance and Biotransformation of [14C]HSK7653 in Human
|
Phase 1 | |
Completed |
NCT02429258 -
Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin
|
Phase 4 | |
Completed |
NCT01055223 -
Fracture Risk With Thiazolidinediones
|
N/A | |
Terminated |
NCT02365233 -
Fatty Liver Study in Patients With Type II Diabetes
|
Phase 4 | |
Completed |
NCT05878587 -
Burger Allen Exercises in Knee OA With Type II Diabetes
|
N/A | |
Completed |
NCT04768673 -
A Study to Investigate the PK and Safety of CKD-393
|
Phase 1 | |
Not yet recruiting |
NCT05028140 -
Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus
|
Phase 3 | |
Terminated |
NCT01804777 -
Epithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes
|
Early Phase 1 | |
Completed |
NCT01619332 -
Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT06387433 -
Effectiveness of an mHealth Mobile App
|
N/A | |
Completed |
NCT01881074 -
Periodontal Treatment Response in Type II Diabetic Patients
|